CN102170903B - 用于刺激免疫反应的产品和方法 - Google Patents

用于刺激免疫反应的产品和方法 Download PDF

Info

Publication number
CN102170903B
CN102170903B CN200980125581.9A CN200980125581A CN102170903B CN 102170903 B CN102170903 B CN 102170903B CN 200980125581 A CN200980125581 A CN 200980125581A CN 102170903 B CN102170903 B CN 102170903B
Authority
CN
China
Prior art keywords
cells
antigen
specific
bcr
hel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN200980125581.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN102170903A (zh
Inventor
法存多·巴蒂斯塔
尤利娅·埃克尔-多尔纳
帕特里西亚·巴拉尔
温琴佐·塞伦多罗
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cancer Research Technology Ltd
Original Assignee
Cancer Research Technology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Research Technology Ltd filed Critical Cancer Research Technology Ltd
Publication of CN102170903A publication Critical patent/CN102170903A/zh
Application granted granted Critical
Publication of CN102170903B publication Critical patent/CN102170903B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN200980125581.9A 2008-05-02 2009-05-05 用于刺激免疫反应的产品和方法 Expired - Fee Related CN102170903B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4981408P 2008-05-02 2008-05-02
US61/049,814 2008-05-02
PCT/GB2009/001111 WO2009133378A2 (en) 2008-05-02 2009-05-05 Products and methods for stimulating an immune response

Publications (2)

Publication Number Publication Date
CN102170903A CN102170903A (zh) 2011-08-31
CN102170903B true CN102170903B (zh) 2016-04-06

Family

ID=40888253

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200980125581.9A Expired - Fee Related CN102170903B (zh) 2008-05-02 2009-05-05 用于刺激免疫反应的产品和方法

Country Status (8)

Country Link
US (1) US20110280930A1 (https=)
EP (3) EP2711021B1 (https=)
JP (3) JP5721620B2 (https=)
CN (1) CN102170903B (https=)
AU (1) AU2009241645B2 (https=)
CA (1) CA2723226A1 (https=)
ES (1) ES2570973T3 (https=)
WO (1) WO2009133378A2 (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2711021B1 (en) * 2008-05-02 2016-03-09 BliNK Therapeutics Limited Products and methods for stimulating an immune response
WO2012088414A1 (en) * 2010-12-23 2012-06-28 Ludwig Institute For Cancer Research Ltd. Liposomal formulation of nonglycosidic ceramides and uses thereof
US9675561B2 (en) 2011-04-28 2017-06-13 President And Fellows Of Harvard College Injectable cryogel vaccine devices and methods of use thereof
EP2714017B1 (en) 2011-06-02 2018-08-01 The Regents of The University of California Membrane encapsulated nanoparticles and method of use
TW201442739A (zh) * 2013-02-27 2014-11-16 Riken 過敏疾病治療藥
GB2514591A (en) 2013-05-30 2014-12-03 Mologen Ag Predictive biomarker for cancer therapy
EP3024936B1 (en) 2013-07-25 2019-09-04 Exicure, Inc. Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use
WO2015021390A2 (en) 2013-08-08 2015-02-12 The Regents Of The University Of California Nanoparticles leverage biological membranes to target pathogens for disease treatment and diagnosis
US20170000875A1 (en) * 2013-12-02 2017-01-05 Arytha Biosciences, Llc Toxoid preparation and uses thereof
CN106163504B (zh) 2014-03-20 2021-02-09 加利福尼亚大学董事会 水凝胶毒素-吸收或结合纳米颗粒
EP3137105A4 (en) 2014-04-30 2017-12-27 President and Fellows of Harvard College Combination vaccine devices and methods of killing cancer cells
TR201908550T4 (tr) * 2014-06-04 2019-07-22 Exicure Inc Profilaktik veya terapötik uygulamalar için lipozomal sferik nükleik asitler tarafından immün modülatörlerin çok değerlikli teslimi.
WO2016164705A1 (en) * 2015-04-10 2016-10-13 Omar Abdel-Rahman Ali Immune cell trapping devices and methods for making and using the same
WO2016176041A1 (en) 2015-04-29 2016-11-03 The Regents Of The University Of California Detoxification using nanoparticles
JP2018516996A (ja) * 2015-06-10 2018-06-28 ウニヴェルズィテート・デ・ザールラントＵｎｉｖｅｒｓｉｔａｅｔ Ｄｅｓ Ｓａａｒｌａｎｄｅｓ Ｂ細胞悪性腫瘍を処置するための手段および方法
US11752238B2 (en) 2016-02-06 2023-09-12 President And Fellows Of Harvard College Recapitulating the hematopoietic niche to reconstitute immunity
WO2017211314A1 (en) 2016-06-08 2017-12-14 Kei International Limited Method for detecting presence of mycobacterial material in sample using immobilised mannosyl phosphoketide antigen
NL2017204B1 (en) 2016-06-08 2017-12-18 Kei International Ltd Solid substrate comprising antigens immobilised thereto, biosensor comprising said solid substrate and method for detecting the presence of mycobacterial material in a sample
CN109789092A (zh) 2016-07-13 2019-05-21 哈佛学院院长等 抗原呈递细胞模拟支架及其制备和使用方法
IL264557B2 (en) 2016-08-02 2024-01-01 Harvard College Biological agents for regulating immune responses
US20190365657A1 (en) * 2016-08-17 2019-12-05 Orbis Health Solutions, Llc Tumor-targeting bead vectors and methods of using the same
WO2019032862A1 (en) * 2017-08-10 2019-02-14 Dana-Farber Cancer Institute, Inc. CELLS EXPRESSING LMP1 AND METHODS OF USE
NL2021443B1 (en) 2018-08-08 2020-02-20 Kei International Ltd Synthetic antigens for tuberculosis detection
WO2020061129A1 (en) 2018-09-19 2020-03-26 President And Fellows Of Harvard College Compositions and methods for labeling and modulation of cells in vitro and in vivo
EP3650466A1 (en) * 2018-11-12 2020-05-13 Consejo Superior De Investigaciones Científicas In vitro production of high affinity monoclonal antibodies
CN111229023B (zh) * 2018-11-29 2022-01-28 内蒙古东盛硅藻土科技创新产业园有限公司 一种化学降解添加剂
WO2021061837A1 (en) 2019-09-23 2021-04-01 President And Fellows Of Harvard College Biomaterial-based antigen free vaccine and the use thereof
CN112300987B (zh) * 2020-10-16 2022-04-29 中国农业大学 单个浆细胞的筛选方法及其在小分子单克隆抗体制备中的应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK590288D0 (da) 1988-10-24 1988-10-24 Symbicom Ab Kemiske forbindelser
DK0506868T4 (da) 1989-12-22 2004-04-26 Mikrogen Molekularbiol Entw Immunologisk aktive proteiner fra Borrelia burgdorferi, tilhørende testkits og vaccine
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
FI933580A7 (fi) 1991-02-15 1993-10-13 Uab Research Foundation Pneumokokkiproteiinin rakennegeeni
US6113914A (en) 1991-08-15 2000-09-05 Smithkline Beecham Biologicals (S.A.) Osp A proteins of Borrelia burgdorferi subgroups, encoding genes and vaccines
ES2194010T3 (es) 1991-10-22 2003-11-16 Symbicom Ab Mejoras en el diagnostico y profilaxis de la borrelia burgdorferi.
US5776427A (en) 1992-03-05 1998-07-07 Board Of Regents, The University Of Texas System Methods for targeting the vasculature of solid tumors
US6004763A (en) * 1992-09-11 1999-12-21 Institut Pasteur Antigen-carrying microparticles and their use in the induction of humoral or cellular responses
FR2695563B1 (fr) * 1992-09-11 1994-12-02 Pasteur Institut Microparticules portant des antigènes et leur utilisation pour l'induction de réponses humorales ou cellulaires.
EP0773993A4 (en) 1994-08-19 2000-07-05 Gen Hospital Corp PORCINE CELLS TREATED BY GENETIC ENGINEERING
EP1434859A2 (en) 2001-07-25 2004-07-07 New York University Use of glycosylceramides as adjuvants for vaccines against infections and cancer
DE10164309A1 (de) * 2001-12-28 2003-07-10 Fraunhofer Ges Forschung Verbesserte strukturiert-funktionale Bindematrices für Biomoleküle
CN100455600C (zh) * 2002-08-14 2009-01-28 阿维迪斯公司 包含支架,佐剂和抗原的异源多聚体化合物及其用途
AU2004215125B2 (en) 2003-02-26 2011-01-06 Institute For Research In Biomedicine Monoclonal antibody production by EBV transformation of B cells
US20050175583A1 (en) * 2003-12-02 2005-08-11 Lawrence Tamarkin Methods and compositions for the production of monoclonal antibodies
EP1767216B1 (en) 2004-06-11 2012-07-11 Riken Drug having regulatory cell ligand contained in liposome
JP4987704B2 (ja) * 2004-07-07 2012-07-25 スタテンス セールム インスティトゥート 糖脂質を用いた、脂質系アジュバント製剤を安定化する組成物及び方法
EP1793863B1 (en) * 2004-10-01 2017-04-12 Midatech Ltd. Nanoparticles comprising antigens and adjuvants capable of stimulating t helper cells
US20080138431A1 (en) * 2005-03-02 2008-06-12 James Edward Eyles Pharmaceutical Composition
BRPI0617687A2 (pt) 2005-10-25 2011-08-02 Ludwig Inst Cancer Res composto, método para proteger um indivìduo mamìfero contra, ou tratar, um vìrus, infecção microbiana, parasita, uma doença auto-imune, cáncer, alergia ou asma, e, composição farmacêutica
WO2007051004A2 (en) 2005-10-28 2007-05-03 The Brigham And Women's Hospital, Inc. Conjugate vaccines for non-proteinaceous antigens
US20070231344A1 (en) 2005-10-28 2007-10-04 The Brigham And Women's Hospital, Inc. Conjugate vaccines for non-proteinaceous antigens
EP2711021B1 (en) * 2008-05-02 2016-03-09 BliNK Therapeutics Limited Products and methods for stimulating an immune response
JP5782775B2 (ja) 2011-03-29 2015-09-24 ソニー株式会社 情報表示装置および情報表示方法、並びにプログラム

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
B CELLS EXTRACT AND PRESENT IMMOBILIZATION ANTIGEN: IMPLICATIONS FOR AFFINITY DISCRIMINATION;BATISTA F D ET AL;《EMBO JOURNAL》;20000130;第19卷(第4期);第513-520页 *
Effect of different hapten-carrier conjugation ratios and molecular orientations on antibody affinity against a peptide antigen;PEDERSEN M K ET AL;《JOURNAL OF IMMUNOLOGICAL METHODS》;20060420;第311卷(第1-2期);第198-206页 *
Listeriolysin O is an improved protein carrier for lymphoma immunoglobulin idiotype and provides systemic protection against 38C13 lymphoma;PAUL NEESON ET AL;《CANCER IMMUNOLOGY, IMMUNOTHERAPY》;20070918;第57卷(第4期);第493-505页 *
Multivalent compounds for antigen-specific B cell tolerance and treatment of autoimmune diseases.;JONES DAVID S;《CURRENT MEDICINAL CHEMISTRY 2005》;20051231;第12卷(第16期);第1887-1904页 *

Also Published As

Publication number Publication date
EP2711020A1 (en) 2014-03-26
EP2711020B1 (en) 2016-08-10
HK1190942A1 (en) 2014-07-18
EP2711021B1 (en) 2016-03-09
WO2009133378A3 (en) 2009-12-23
CA2723226A1 (en) 2009-05-11
HK1191548A1 (en) 2014-08-01
EP2711021A1 (en) 2014-03-26
JP5853068B2 (ja) 2016-02-09
AU2009241645A1 (en) 2009-11-05
EP2288381A2 (en) 2011-03-02
AU2009241645B2 (en) 2014-07-17
JP2015028023A (ja) 2015-02-12
CN102170903A (zh) 2011-08-31
ES2570973T3 (es) 2016-05-23
HK1161542A1 (zh) 2012-07-27
JP5721620B2 (ja) 2015-05-20
JP2015038066A (ja) 2015-02-26
WO2009133378A2 (en) 2009-11-05
JP2011519847A (ja) 2011-07-14
US20110280930A1 (en) 2011-11-17

Similar Documents

Publication Publication Date Title
CN102170903B (zh) 用于刺激免疫反应的产品和方法
Pedersen et al. Vaccine adjuvants differentially affect kinetics of antibody and germinal center responses
US9950025B2 (en) Compositions and methods for treatment of neoplastic disease
BRPI0616770A2 (pt) modulação de respostas imunes mediadas por tlr empregando oligonucleotìdeos adaptadores
WO2022212564A1 (en) Targeting multiple t cell types using spherical nucleic acid vaccine architecture
US20180037650A1 (en) Pain Treatment
CN103608032A (zh) 用于抑制免疫应答的方法
WO2024086799A2 (en) Lipid nanoparticles and methods of using the same for treating cell proliferative diseases and disorders
AU2014250631B2 (en) Products and methods for stimulating an immune response
HK1161542B (en) Products and methods for stimulating an immune response
US20210015914A1 (en) Methods and compositions related to accelerated humoral affinity
HK1190942B (en) Products and methods for stimulating an immune response
HK1191548B (en) Products and methods for stimulating an immune response
Belcher et al. A particulate saponin/TLR agonist vaccine adjuvant alters lymph flow and modulates adaptive immunity
HK1191562A (en) Method for suppressing an immune response

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1161542

Country of ref document: HK

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20151016

Address after: English Marlowe

Applicant after: Cancer Rec Tech Ltd.

Address before: London, England

Applicant before: Cancer Rec Tech Ltd.

C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20160406

Termination date: 20170505

CF01 Termination of patent right due to non-payment of annual fee